Fluid Biomed Appoints Veteran MedTech Executive John Kilcoyne as Independent Board Chair
Fluid Biomed Inc. (“Fluid Biomed”), a medical device company dedicated to advancing neurovascular innovation, today announced the appointment of John Kilcoyne as Independent Chair of its Board of Directors. Mr. Kilcoyne’s appointment broadens the company’s sector expertise as it accelerates development of its unique polymer-based stent technology to treat brain aneurysms and stroke.
Fluid Biomed Inc. Raises $27 Million USD in Oversubscribed Series A Financing to Advance World’s First Bioabsorbable Polymer-Based Stent To Treat Brain Aneurysms
Fluid Biomed Inc., a clinical stage medical device company developing lifesaving products for patients suffering from vascular disease, closed an oversubscribed $27 million USD Series A equity financing. The round is co-led by Amplitude Ventures and an undisclosed major strategic partner. New participants in the investment syndicate include IAG Capital Partners and LifeArc Ventures, as well as returning investors, ShangBay Capital and METIS Innovative.
